JAKi appear to be an effective and safety therapy in refractory GCA to cDMARDs and/or bDMARDs. Abs 0464 #ACR22 @RheumNow https://t.co/0ZjI8uTgnY https://t.co/OgxND7HrXj
Links:
JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Ca…
http://ow.ly/QXUM50LvuHB
12-11-2022
